BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, Rubinstein SM, Hall R, Wyatt H, Piazza G. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol 2020;190:555-61. [PMID: 32314352 DOI: 10.1111/bjh.16653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-garcía LA, Bounameaux H, Pabinger I, Douketis J, Ageno W, Ajauro F, Alcindor T, Angchaisuksiri P, Arcelus JI, Barba R, Bazarbachii A, Bellesoeur A, Bensaoula O, Benzidia I, Bita D, Bitsadze V, Blickstein D, Blostein M, Bogalho I, Brandao A, Calado R, Carpentier A, Ceresetto JM, Chitsike R, Connault J, Correia CJ, Crichi B, De Paula EV, Demir AM, Deville L, Doucet L, Dounaevskaia V, Durant C, Ellis M, Emmerich J, Falanga A, Font C, Gallardo E, Gary T, Gonçalves F, Gris J, Hayashi H, Hij A, Jara-palomares L, Jiménez D, Khizroeva J, N'guessan M, Langer F, Le Hello C, Le Maignan C, Lecumberri R, Lee LH, Liederman Z, Lopes dos Santos L, Machado DH, Makatsariya A, Maneyro A, Marjanovic Z, Milhaileanu S, Monreal M, Morais S, Moreira A, Mukai M, Ndour A, Correa Oliveira L, Otero-candelara R, Tostes Pintao MC, Posch F, Prilollet P, Rafii H, Dias Ribeiro D, Riess H, Righini M, Robert-ebadi H, Rothschild C, Roussin A, Rueda Camino JA, Ruiz-artacho P, Saharov G, Santos J, Sebuhyan M, Shamseddine A, Spectre GS, Taher A, Trujillo-santos J, Tzoran I, Villiers S, Wong R, Yamashita Y, Yannoutsos A, Yasuda C. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. The Lancet Oncology 2022;23:e334-47. [DOI: 10.1016/s1470-2045(22)00160-7] [Reference Citation Analysis]
2 Nicol M, Siguret V, Vergaro G, Aimo A, Emdin M, Dillinger JG, Baudet M, Cohen-Solal A, Villesuzanne C, Harel S, Royer B, Arnulf B, Logeart D. Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Fail 2021. [PMID: 34784656 DOI: 10.1002/ehf2.13701] [Reference Citation Analysis]
3 Ciepiela O, Małecka-Giełdowska M, Czyżewska E. Neutrophil Extracellular Traps (NETs) and Hypercoagulability in Plasma Cell Dyscrasias-Is This Phenomenon Worthy of Exploration? J Clin Med 2021;10:5243. [PMID: 34830525 DOI: 10.3390/jcm10225243] [Reference Citation Analysis]
4 Barrett A, Quinn J, Lavin M, Thornton P, O'Donnell J, Murphy P, Glavey S. Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. J Clin Med 2021;10:3536. [PMID: 34441832 DOI: 10.3390/jcm10163536] [Reference Citation Analysis]
5 Pozzi S, Bari A, Pecherstorfer M, Vallet S. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers (Basel) 2021;13:4978. [PMID: 34638462 DOI: 10.3390/cancers13194978] [Reference Citation Analysis]
6 Das A, Dasgupta S, Gong Y, Shah UA, Fradley MG, Cheng RK, Roy B, Guha A. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials. Hematol Oncol 2021. [PMID: 34940983 DOI: 10.1002/hon.2959] [Reference Citation Analysis]
7 Rubinstein SM, Tuchman SA. Thrombosis in the modern era of multiple myeloma. Blood 2020;136:1019-21. [DOI: 10.1182/blood.2020006648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Parnes A, Leblebjian H, Hamilton J, Smith S, Laubach J, Berliner N. Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system. J Oncol Pharm Pract 2021;:1078155221995885. [PMID: 33611974 DOI: 10.1177/1078155221995885] [Reference Citation Analysis]
9 Miceli TS, Gonsalves WI, Buadi FK. Supportive care in multiple myeloma: Current practices and advances. Cancer Treat Res Commun 2021;29:100476. [PMID: 34653748 DOI: 10.1016/j.ctarc.2021.100476] [Reference Citation Analysis]
10 Smythe MA, Burns C, Liu Q, Garwood CL. Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID? Ann Pharmacother 2021;:10600280211025042. [PMID: 34137279 DOI: 10.1177/10600280211025042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang TF, Billett HH, Connors JM, Soff GA. Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps. Oncologist 2021;26:e17-23. [PMID: 33275323 DOI: 10.1002/onco.13570] [Reference Citation Analysis]
12 Santoro M, Romano A, Mancuso S, Siragusa S, DI Raimondo F, Martinelli G, Cerchione C. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. Panminerva Med 2021;63:1-6. [PMID: 32955183 DOI: 10.23736/S0031-0808.20.04133-6] [Reference Citation Analysis]
13 Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, Mailankody S, Lesokhin A, Shah U, Lu S, Patel D, Derkach A, Wilkins CR, Korde N. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol 2021. [PMID: 34396516 DOI: 10.1111/bjh.17772] [Cited by in F6Publishing: 1] [Reference Citation Analysis]